Goldman Sachs
PYXS icon

Goldman Sachs’s Pyxis Oncology PYXS Stock Holding History

Goldman Sachs’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.5K Sell
46,920
-39,225
-46% -$59.1K ﹤0.01% 6263
2025
Q4 		$99.1K Sell
86,145
-39,309
-31% -$139K ﹤0.01% 6188
2025
Q3 		$279K Sell
125,454
-98,820
-44% -$142K ﹤0.01% 5797
2025
Q2 		$247K Buy
224,274
+63,444
+39% +$71.5K ﹤0.01% 5554
2025
Q1 		$158K Sell
160,830
-23,872
-13% -$31.9K ﹤0.01% 5686
2024
Q4 		$288K Buy
184,702
+45,570
+33% +$131K ﹤0.01% 5513
2024
Q3 		$511K Buy
139,132
+21,884
+19% +$76.6K ﹤0.01% 5041
2024
Q2 		$388K Sell
117,248
-219,443
-65% -$923K ﹤0.01% 4966
2024
Q1 		$1.43M Buy
+336,691
New +$1.42M ﹤0.01% 4098
2023
Q3 		– Sell
-45,974
Closed -$118K – 5796
2023
Q2 		$118K Buy
45,974
+10,550
+30% +$33.5K ﹤0.01% 5329
2023
Q1 		$142K Buy
+35,424
New +$70.8K ﹤0.01% 5397
2022
Q3 		– Sell
-12,882
Closed -$31K – 6482
2022
Q2 		$31K Buy
+12,882
New +$34.3K ﹤0.01% 6119

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's PYXS Position: Q1 2026 in Review

Goldman Sachs reduced its Pyxis Oncology (PYXS) stake by 46% in Q1 2026, selling an estimated $59.1K and leaving 46,920 shares worth $68.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6263.

Goldman Sachs first reported a position in PYXS in Q2 2022 and has held it in 12 quarters since. The position peaked at $1.43M in Q1 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Goldman Sachs held 46,920 shares of Pyxis Oncology worth $68.5K as of Q1 2026.
  • Goldman Sachs sold 39,225 Pyxis Oncology shares in Q1 2026, an estimated $59.1K.
  • Pyxis Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6263 holding.
  • Goldman Sachs first reported a position in Pyxis Oncology in Q2 2022 and has held it in 12 quarters since.
  • Goldman Sachs's Pyxis Oncology position peaked at $1.43M in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.